Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
TAC-001 by Tallac Therapeutics for Colorectal Cancer: Likelihood of Approval
TAC-001 is under clinical development by Tallac Therapeutics and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...
Data Insights
TAC-001 by Tallac Therapeutics for Metastatic Melanoma: Likelihood of Approval
TAC-001 is under clinical development by Tallac Therapeutics and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase...